PRINCETON, N.J. — November 11, 2025 — Leads & Copy — Integra LifeSciences Holdings Corporation (Nasdaq: IART) announced that the FDA has cleared its CUSA® Clarity Ultrasonic Surgical Aspirator System for use in cardiac surgeries. The clearance includes debridement of unwanted tissue during valve replacement and repair.
In addition to cardiac surgery, the CUSA Clarity system can be used in neurosurgery, plastic and reconstructive surgery, orthopedic surgery, thoracic surgery, laparoscopic surgery, gynecological surgery, and liver resection and transplant surgery, Integra LifeSciences said.
Mike McBreen, executive vice president and president of Integra’s Codman Specialty Surgical division, said that the cardiac surgery clearance marks a pivotal expansion and strengthens their ability to deliver advanced surgical solutions.
Integra LifeSciences will showcase the CUSA Clarity Ultrasonic Surgical Aspirator System at the American Association for Thoracic Surgeon Mitral Valve Conclave in New York City on December 11 and 12, 2025.
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader focused on neurosurgery and tissue reconstruction.
Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
Source: Integra LifeSciences
